The objective of this study was to investigate a novel drug delivery system, ADSCs-EXO-ICA, which co-delivers drugs to facilitate the M1-to-M2 phenotypic switch by down-regulating glycolysis through blocking the ERK/HIF-1α/GLUT1 pathway, thus mitigating the RA progression. This evidence concerns the gene HIF1A and rheumatoid arthritis.